There were 1,368 press releases posted in the last 24 hours and 392,713 in the last 365 days.

BioElectronics Appoints Southeast Asia Distributor

FREDERICK, MD - (NewMediaWire) - November 01, 2016 - BioElectronics Corporation (OTC PINKBIEL), the maker of advanced consumer pain management medical devices, today announced that it has appointed PharmEvo as its ActiPatch® Musculoskeletal Pain Therapy distributor for Vietnam, Kenya, Cambodia, Myanmar, Kenya and Sri Lanka.

PharmEvo was established in 1999, has a sales team of 850 people, and annual sales of over $300 million. Corporate headquarters are in Karachi, Pakistan with 9 locations in Pakistan and international market coverage in Vietnam, Cambodia, Kenya, Philippines, Myanmar, Sri Lanka, Guatemala, Kenya, Tanzania, Pakistan, Kazakhstan, and Uzbekistan. PharmEvo engaged in the creation, development, manufacture and marketing of pharmaceutical products, including over-the-counter (OTC) medicines, medical equipment and infant formulas. PharmEvo partners with the following international groups for bringing best quality products to its consumers: Bioton (Poland), Lactalis (France), Omron (Japan), Becton Dickson (USA), etc.

Nadeem Rehmat, Director of PharmaEvo Business Development has expressed his confidence that ActiPatch Musculoskeletal drug-free inexpensive pain therapy is a great fit to their OTC line. 

"We are pleased to have PharmEvo selling our ActiPatch products in Southeast Asia. We believe our unique cost effective drug-free pain therapy will have excellent market acceptance in Asia," said Erin Sanders, BioElectronics Sales Manager. 

About BioElectronics Corporation  BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic wounds and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit